Dr. Brown is a Professor and Chair of Neurology at UMass Medical School (Worcester, MA).

Biofocus is a Contract Research Organization.

Dr. Bashir is a Lecturer in Biological and Biomedical Sciences, School of Biological and Biomedical Sciences, University of Durham (Durham, UK).

Dr. Barton is an Assistant Professor of Anatomy and Cell Biology in the University of Pennsylvania School of Dental Medicine (Philadelphia, PA).

Dr. Balcin is a postdoctoral research fellow at the Karolinska Institute in the Department of Neurophysiology and Neurology in Stockholm, Sweden.

David Baker, PhD is the Head of the Institute for Protein Design and a Professor of Biochemistry at the University of Washington (Seattle, Washington)

Charles River Discovery Research Services offers preclinical models with imaging, behavior and biomarkers. With this modeling platform, their aim is to provide as much informatio as possible that is readily translatable to clinical studies.

Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development, cell therapy, tissue engineering and organ regeneration. CDI harnesses its unique manufacturing technology to produce differentiated tissue cells from any individual’s stem cell line in industrial quality, quantity and purity. CDI is accelerating the adoption of pluripotent stem cell technology, adapting its methods to fit into standard clinical practice by the creation of individual stem cell lines from a standard blood draw. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI’s facilities are located in Madison, Wisconsin. See http://www.cellulardynamics.com.

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. They operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals Inc., Medimmune/AstraZeneca, Roche and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim, MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and Roche in the field of Alzheimer's disease. For additional information please go to http://www.evotec.com.